Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene

NEW YORK, May 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.

--
Merck & Co. Inc. Analyst Notes
On May 8, 2014, Merck & Co. Inc. (Merck) along with AiCuris GmbH & Co KG (AiCuris) announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. The Company informed that the results published in the latest issue of the New England Journal of Medicine (NEJM) demonstrates that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow transplant patients) met the study's two primary efficacy endpoints. Dr. Eliav Barr, Vice President, Infectious Diseases, Merck Research Laboratories, commented, "Based on the data from this study, and Merck's own evaluations, we are pleased to be moving forward with plans to initiate a Phase 3 trial of letermovir in the first half of this year." Merck added that it plans to conduct a Phase 3 trial of letermovir, also known as AIC246 or MK-8228, beginning H1 2014. The full analyst notes on Merck are available to download free of charge at:

http://www.analystsreview.com/2377-MRK-13May2014.pdf

--
Johnson & Johnson Analyst Notes
On May 6, 2014, a pharmaceutical company of Johnson & Johnson, Janssen Pharmaceuticals, Inc. (Janssen) announced the results of its schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate). The Company informed that the trial confirmed that INVEGA® SUSTENNA® met its primary endpoint of delayed time to and reduced risk of relapse versus placebo as monotherapy and adjunctive therapy in patients with schizoaffective disorder. The Company informed that the study results were presented at the 167th Annual Meeting of the American Psychiatric Association (APA) in New York City and support the filing of a supplemental New Drug Application (sNDA) by the end of May 2014 for the treatment of schizoaffective disorder for INVEGA® SUSTENNA®. The full analyst notes on JNJ are available to download free of charge at:

http://www.analystsreview.com/2377-JNJ-13May2014.pdf

--
Chelsea Therapeutics International Ltd. Analyst Notes
On May 8, 2014, Chelsea Therapeutics International Ltd. (Chelsea) announced that the Company has entered into a definitive agreement to be acquired by H. Lundbeck A/S (Lundbeck), a global pharmaceutical Company that specializes in brain diseases. Pursuant to the terms of the agreement, Lundbeck will begin a tender offer for all outstanding shares of Chelsea, in which Chelsea stockholders will be offered an upfront payment and contingent value rights (CVRs), representing a total potential consideration of up to $7.94 per share, or $658 million on a fully diluted basis. Chelsea informed that the acquiring company, Lundbeck plans to buy any shares of Chelsea not tendered into the tender offer through a merger for the same per share consideration as will be payable in the tender offer. The full analyst notes on Chelsea are available to download free of charge at:

http://www.analystsreview.com/2377-CHTP-13May2014.pdf

--
Unitedhealth Group, Inc. Analyst Notes
On May 6, 2014, Unitedhealth Group, Inc. (Unitedhealth) and Arizona Care Network, jointly introduced an accountable care organization (ACO) to improve care quality and reduce costs for nearly 15,000 Phoenix-area residents enrolled in UnitedHealthcare's employer-sponsored health plans. The Companies informed that the ACO collaboration will enable Arizona Care Network's primary care physicians, hospitals and home health care providers to improve transitions of care for patients and aid better communication with all who are involved in a patient's treatment. Beth Soberg, President and CEO, UnitedHealthcare of Arizona, commented, "UnitedHealthcare's new partnership with Arizona Care Network is the latest example of how we are working closely with the care provider community to enhance the way care is delivered to patients." The full analyst notes on Unitedhealth are available to download free of charge at:

http://www.analystsreview.com/2377-UNH-13May2014.pdf

--
Celgene Corporation Analyst Notes
On May 7, 2014, Celgene Corporation (Celgene) announced the pricing of three series of senior unsecured notes for an aggregate principal amount of $2,500 million. The Company informed that of these notes $500 million will mature in 2019 and will bear interest at an annual rate of 2.25%; $1,000 million will mature in 2024 and will bear interest at an annual rate of 3.63% and $1,000 million will mature in 2044 and will bear interest at an annual rate of 4.63%, priced to yield 2.30%, 3.67% and 4.65%, respectively. Celgene informed that it expects to use the net proceeds from the offering for general corporate purposes. The offering is expected to close on May 15, 2014. The full analyst notes on Celgene are available to download free of charge at:

http://www.analystsreview.com/2377-CELG-13May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review